Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Investor Day (September 2026)
113 slides from Telix Pharmaceuticals's investor day presentation, Sep 22, 2026
Slide 1: R&D Day
R&D Day September 22, 2026 ASX: TLX | NASDAQ: TLX
Slide 2: Forward looking statement
Forward looking statement This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on
Slide 3: Today's presenters – Telix management
Today’s presenters – Telix management Dr. Christian Behrenbruch Mr. Kevin Richardson Mr. Richard Valeix Dr. David N. Cade, MD Dr. Michael Wheatcroft Managing Director and CEO, Precision Medicine CEO, Therapeutics Group Chief Medical Officer Vice President Discovery Group CEO Sciences 3
Slide 4: Key Opinion Leaders
Key Opinion Leaders Dr. Alicia Morgans Dr. Varun Sundaram Dr. Sumanta Pal Dr. Arthur Braat Associate Professor of Surgical Urologist Professor and Vice Associate Professor Medicine Harvard and Advanced Chair of Academic Translational Nuclear Medical School, Director Prostate Cancer Affairs, Departme
Slide 5: Strategy & overview
Strategy & overview Dr. Christian Behrenbruch Managing Director and Group CEO
Slide 6: Five pillars defining our competitive leadership in radiopharma
Five pillars defining our competitive leadership in radiopharma Integrated Theranostic Approach See It. Treat It. High value R&D platform for Precision Specialist Vertically therapeutics new molecular Medicine commercial integrated pipeline entities portfolio organization manufacturing and supply ch
Slide 7: Three FDA approvals across prostate and glioma imaging
Three FDA approvals across prostate and glioma imaging • First FDA-approved FET- • Launched in 22 PET imaging drug for countries1 glioma4 • 17 countries1 in Europe • Included in National • NDA under review by Comprehensive Cancer NMPA in China2 Network (NCCN®) • Registration enabling guidelines stud
Slide 8: A proven track record of commercial execution
A proven track record of commercial execution Revenue has more than doubled since 2024 Near-term growth drivers 247 REVENUE US$M 230 204 206 208 186 135 142 124 115 ® 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 Note: Zircaix and BiPASS have not been evaluated, approved, or cleared by the FDA t
Slide 9: Creating a fully integrated global radiopharma leader
Creating a fully integrated global radiopharma leader Building on U.S. success to drive global growth Marketing authorizations granted Ongoing clinical trials Sale allowed under special exemption (South Korea and New Zealand) 9
Slide 10: Global network enables just-in-time delivery at commercial scale
Global network enables just-in-time delivery at commercial scale Opens new market opportunities for Telix’s products 1 3x manufacturing Global HQ & 2x sites & 2x manufacturing >99% cyclotrons in BE sites in DE Order fulfillment rate (2025A) Just-in-time delivery: 24-48hr within EU/US and 72hr JV acr
Slide 11: Strategic investments and partnerships for long-term growth
Strategic investments and partnerships for long-term growth Capabilities across manufacturing & supply, R&D and isotope production Commercialization Development 1 Discovery Research 2023 2024 2025 2026 1. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval,
Slide 12: Telix + ITM creates a differentiated and scaled global platform
Telix + ITM creates a differentiated and scaled global platform Three complementary growth engines under one platform Best-in-class radioisotope Industry’s most advanced Scaled commercial manufacturing and supply therapeutic pipeline precision medicine • Global radioisotope demand • Potential near-t
Slide 13: Transaction reinforces Telix's growth strategy
Transaction reinforces Telix’s growth strategy The combination of ITM + Telix enhances our ability to compete Vertically High value Precision Specialist R&D platform integrated manufacturing / therapeutics Medicine commercial for new supply chain pipeline portfolio organization molecular entities Va
Slide 14: R&D Strategy
R&D Strategy Dr. Michael Wheatcroft VP, Discovery Sciences
Slide 15: Target selection: Unlocking the advantages of targeted radiation
Target selection: Unlocking the advantages of targeted radiation Our approach to target selection • Tumor-specific antigens that enable a favorable therapeutic window • High target prevalence in the selected indication • High expression to maximize efficient radiation delivery • Internalizing target
Slide 16: Optimized targeting agents drive next-generation candidates
Optimized targeting agents drive next-generation candidates Different formats offer different Small Nanobody scFv Diabody Minibody scFv-Fc IgG△CH2 IgG features; trade-offs for delivery to and molecule/ interaction with the cancer cell peptide Accessing a diversity of formats with different propertie
Slide 17: Minibody candidates advancing into the clinic
Minibody candidates advancing into the clinic Minibody targeting agent TLR602-Tx [212Pb/225Ac] TLR603-Tx [212Pb/225Ac] Target: αvβ6 Integrin Target: DLL3 (Delta Like Ligand-3) Potential indications: Potential indications: Alpha-Payload: Non-Small Cell Lung Cancer, NSCLC Small Cell Lung Cancer, SCLC
Slide 18: Matching alpha and beta emitters to tumor biology
Matching alpha and beta emitters to tumor biology Radioisotope paired to utility α vs β Therapeutic radiation • Emission profile • Half-life vs pharmacokinetics • Depth of penetration β-Radiation • Tumor size / distribution • Tumor microenvironment & heterogeneity • Supply chain considerations Match
Slide 19: Global manufacturing, distribution & clinical support capabilities
Global manufacturing, distribution & clinical support capabilities Seneffe, Belgium GMP3 capacity to deliver therapeutics ARTMS QIS® technology, enabling highly efficient, cost-effective isotope Yokohama, Japan production ARTMS QIS® for isotope production Sacramento, U.S. Clinical manufacture Multip
Slide 20: De-risking therapeutic development through early imaging studies
De-risking therapeutic development through early imaging studies TOP: 89Zr-girentuximab PET/CT at baseline showing uptake in a sacral metastatic lesion in a patient with ccRCC. Imaging Therapeutics Imaging complements Therapeutic development ✓ Confirms clinical proof of concept ✓ Provides safety dos
Slide 21: Pipeline Overview
Pipeline Overview Mr. Richard Valeix CEO, Therapeutics
Slide 22: Pipeline: Late-stage and next generation assets
Pipeline: Late-stage and “next generation” assets Pixlumi, Zircaix brand names subject to regulatory approval. PSMA: Prostate-specific membrane antigen. PDGFRα: Platelet-derived growth factor receptor alpha. CAIX: Carbonic anhydrase IX. mAb: Monoclonal antibody. LAT1: L-Type amino acid transporter 1
Slide 23: Transformative portfolio expansion across early and late-stage assets
Transformative portfolio expansion across early and late-stage assets • Co-development and co-commercialization • Adds a complementary therapeutic franchise agreement to develop candidates focused on with multiple pathways for growth alpha therapies • ITM-11 Phase 3 expansion programs create • 4 ini
Slide 24: Prostate Cancer Overview
Prostate Cancer Overview Dr. Alicia Morgans Associate Professor of Medicine at Harvard Medical School Genitourinary Medical Oncologist at Dana-Farber Cancer Institute
Slide 25: Prostate Cancer: Disease Overview
Prostate Cancer: Disease Overview Most common cancer in men, second leading cause of cancer death in U.S.1 Annual Incidence (US)1 • 1 in 8 men diagnosed with prostate cancer during their lifetime, 1 in 44 patients die from it1 • Projected U.S. figures for 20261: - 333,830 new prostate cancer diagnos
Slide 26: Prostate Cancer patient journey
Prostate Cancer patient journey Global Standards of Care (SoC) continue to evolve Treatment algorithm for metastatic prostate cancer1 mAPMN/S 1L mAPMR 2L mAPMR 3L+ mAPMR (mHSPC) (mCRPC) (mCRPC) (mCRPC) • ARPI • ARPI • Taxane • Taxane for high volume • Taxane • 177Lu-PSMA-617 post-taxane2 disease • 1
Slide 27: Advancing beyond first generation PSMA RLT
Advancing beyond first generation PSMA RLT Managing xerostomia (dry mouth) and off-target uptake, remains an important unmet need Xerostomia from salivary gland uptake PSMAddition PSMAfore VISION impacts Quality of Life (QOL): Select USPI Adverse 177Lu-PSMA- 177Lu-PSMA- 177Lu-PSMA- Reactions 617 + A
Slide 28: TLX591-Tx
177Lu TLX591-Tx 177Lu
Slide 29: TLX591-Tx is a novel therapy candidate for prostate cancer
TLX591-Tx is a novel therapy candidate for prostate cancer Radio antibody-drug conjugate (rADC) Mechanism of Action approach addresses key unmet needs1-4 1. Patient friendly 2-dose / 2-week regimen: Supports compliance to treatment and ease of integration with standard of care (SOC) 2. Safety and to
Slide 30: Phase 3 ProstACT Global study for TLX591-Tx
® Phase 3 study for TLX591-Tx Part 1 completed, with FDA alignment to advance to Part 2 in U.S.1 Part 1: Safety and dosimetry: Part 2: Randomized treatment expansion completed TLX591-Tx + Eligible TLX591-Tx (76mCi) x 2 cycles + abiraterone/ Primary endpoints (Part 1) Patients abiraterone enzalutamid
Slide 31: Acceptable safety profile confirmed with no new safety signals
Acceptable safety profile confirmed with no new safety signals Non-hematologic events were low grade, hematologic events were transient and manageable ProstACT Global Part 1 (safety TEAE)1 Key observations Adverse Grade Grade Grade Grade Total % of Event 1 2 3 4 (n) N=36 Treatment emergent adverse e
Slide 32: Hematological events transient and consistent across cohorts
Hematological events transient and consistent across cohorts Platelet counts recovered consistently in all three cohorts at ~15 days post nadir TLX591-Tx (2 doses at 76 mCi each) 1.2 Normalized Platelets (by cohort) Abiraterone Enzalutamide Docetaxel 1.0 n =11 n =14 n =11 0.8 0.6 0.4 Recovery to Gra
Slide 33: TLX591-Tx demonstrated sustained tumor retention across all cohorts
TLX591-Tx demonstrated sustained tumor retention across all cohorts through 15 days Demonstrates sustained activity, consistent across cohorts1 Key observations Blood radioactivity Lesion activity • Predictable PK profile: Low inter- Concentrations-Time Profile Concentrations-Time profile patient va
Slide 34: Organ radiation exposure remained below established safety limits
Organ radiation exposure remained below established safety limits Organ mean absorbed dose (Gy) after 2 cycles of TLX591-Tx (2.81 MBq) Organ mean absorbed dose (Gy) after two cycles of 177Lu-rosopatamab (76mCi)1 Key observations • Liver (clearance organ), colon, rectum, spleen, kidney and red marrow
Slide 35: Patient case: TLX591-Tx (2 doses) + docetaxel
Patient case: TLX591-Tx (2 doses) + docetaxel (6 cycles) 83-year-old patient with bony metastatic lesions1 SPECT TLX591-Tx biodistribution: Single dose Distribution of TLX591-Tx over 15 days2 * Stable disease at day 341 (data cutoff) Post treatment SPECT imaging TLX591-Tx seen in the TLX591-Tx seen
Slide 36: Patient case: TLX591-Tx (2 doses) + abiraterone
Patient case: TLX591-Tx (2 doses) + abiraterone 64-year-old patient with metastatic disease in lymph nodes1 SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days * Stable disease for 339 days Post treatment SPECT imaging TLX591-Tx seen in the TLX591-Tx seen at after one
Slide 37: Patient case: TLX591-Tx (2 doses) + enzalutamide
Patient case: TLX591-Tx (2 doses) + enzalutamide 62 year-old patient with prior ARPI (darolutamide) and docetaxel1 SPECT TLX591-Tx biodistribution: Single dose distribution of TLX591-Tx over 15 days * Stable disease and on study at 337 days (data cutoff) Administration TLX591-Tx seen in the TLX591-T
Slide 38: TLX597-Tx
TLX597-Tx Dr. David N. Cade Group Chief Medical Officer, CMO
Slide 39: Disease progression shifts clinical priorities
Disease progression shifts clinical priorities Distinct prostate cancer disease states bear implications for patient management Androgen pathway modulator sensitive Androgen pathway modulator resistant Prognosis and • Survival commonly extends beyond 4-5 • Approximately 2-3 years from initiation of
Slide 40: Addressing patient needs across the care continuum
Addressing patient needs across the care continuum TLX597-Tx and TLX591-Tx profiles are adapted to each disease state TLX597-Tx: Next gen small molecule1 TLX591-Tx: First-in-class rADC2 • Renal excretion BUT with 1/3rd radiation • Liver excretion (radio-tolerant organ) Excretion organ dose to kidney
Slide 41: TLX597-Tx early data suggests favorable dosimetry profile
TLX597-Tx early data suggests favorable dosimetry profile Selective tumor targeting with lower healthy tissue exposure TLX597-Tx SPECT scan, 5 hrs and 120 hrs TLX597-Tx PSMA-6172 PSMA-I&T2 Gy/GBq (n = 12)1 (n = 297) (n = 153) Kidneys 0.28 < 0.58 0.71 Lacrimals 0.35 < 1.58 2.83 Submandibular 0.25 < 0
Slide 42: Leveraging dose intensification and higher activity to enhance tumor response
Leveraging dose intensification and higher activity to enhance tumor response Dose intensification consists of 2 components PSMA up-regulation can be seen 3 days after the initial dose through higher TTV Dose 1 (Day 1) Dose 2 (Day 3) 1 First 3 doses 2 Higher administered administered in 15 days acti
Slide 43: TLX597-Tx, Phase 2 OPTIMAL-PSMA study
TLX597-Tx, Phase 2 OPTIMAL-PSMA study PSA response as Exploring safety and efficacy of dose intensification vs standard treatment well understood surrogate biomarker for small molecules Majority of patients Investigator Initiated Trial (PI: Prof Louise (not for mAbs) Part B received prior Emmett, St
Slide 44: Patient case: TLX597-Tx treatment post-chemo and ARPI
Patient case: TLX597-Tx treatment post-chemo (2 lines) and ARPI Dose 1 Dose 2 Dose 3 Dose 4 (Day 1) (Day 3) (Day 15) (Week 10) 71-year-old patient with diffuse bone metastases • Normal kidney function • Substantial shrinkage of lesions • 97% PSA response at week 10 Day 1 Day 3 Day 15 Week 6 Week 10
Slide 45: Patient case: TLX597-Tx in advanced setting
Patient case: TLX597-Tx in advanced setting Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 (Day 1) (Day 3) (Day 15) (Week 10) (Week 20) Extensive skeletal / bone marrow involvement at baseline • Improvement in hemoglobin • Normal kidney function • 99% PSA response Day 1 Day 3 Day 15 Week 10 Week 20 PSA 487 522
Slide 46: TLX597-Tx, Phase 2 OPTIMAL-e study in mAPMN/S
TLX597-Tx, Phase 2 OPTIMAL-e study in mAPMN/S (mHSPC) Adaptive PSMA targeted radioligand therapy 3 doses in 6 weeks 2 doses every 8-weeks 2 doses every 8-weeks Eligibility Primary endpoint Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 • Minimally Day 1 Day 8 Day 10 Week 6 Week 14 Week 22 Week 30
Slide 47: Beyond Lu-PSMA in Prostate Cancer
Beyond Lu-PSMA in Prostate Cancer 225 Ac
Slide 48: TLX592-Tx: Evaluating two targeting modalities with alpha therapy
TLX592-Tx: Evaluating two targeting modalities with alpha therapy Maximizing tumor delivery while limiting off-target uptake First-generation small molecules Antibody-based approach Small molecule approach TLX592 combines the biodistribution advantages of An optimized small molecule Clinical experie
Slide 49: TLX090-Tx: Novel candidate for pain from bone metastasis
TLX090-Tx: Novel candidate for pain from bone metastasis Phase 1 data1 demonstrate encouraging efficacy signal Positive Phase 1 data Phase 1 program • Debilitating pain from osteoblastic bone Visual Analogue Scale (VAS) measures pain intensity on a scale of 100 0= no pain, 100 = worst pain metastase
Slide 50: Multi-product therapy portfolio in prostate cancer
Multi-product therapy portfolio in prostate cancer Aligned to disease state, patient needs and clinical opportunity Androgen pathway modulator-sensitive Androgen pathway modulator resistant Palliative TLX090-Tx TLX592-Tx TLX597-Tx TLX591-Tx Phase 3 OPTIMAL-e in PSMA+ mAPMR patients previously Phase
Slide 51: BiPASS
BiPASS ® Biopsy of the Prostate Avoidance Stratification Study Dr. Varun Sundaram Urology Austin
Slide 52: Current diagnostic pathway for prostate cancer relies on invasive biopsies
Current diagnostic pathway for prostate cancer relies on invasive biopsies Template biopsy • Template biopsies require 15-20 samples obtained through an invasive procedure under anesthesia • Sampling limitations may miss disease or fail to characterize tumor burden. Biopsies are blind to the tumor l
Slide 53: A significant unmet need remains in the diagnostic pathway
A significant unmet need remains in the diagnostic pathway Men with elevated PSA Biopsies carry real risks4 Areas of biopsy6 values will often be • Hematuria, rectal bleeding, recommended for MRI1, hematospermia Base (top) followed by biopsy • Inconsistent practice around • MRI is not specific and o
Slide 54: Key insights from PRIMARY and PRIMARY 2 Investigator Initiated Studies
Key insights from PRIMARY and PRIMARY 2 Investigator Initiated Studies (IITs) PRIMARY (n = 291)1 Ga-PSMA-PET +mpMRA mpMRI PRIMARY study established Sensitivity 97% 83% proof of concept that Ga- Specificity 40% 53% PSMA-11 PET + mpMRI Negative predictive value 91% 72% improves the detection of PRIMAR
Slide 55: BiPASS Phase 3 study for detection of prostate cancer
® , Phase 3 study for detection of prostate cancer Biopsy of the Prostate Avoidance Stratification Study (BiPASS) Primary Objective: Detection of clinically significant prostate cancer using mpMRI + 68Ga-PSMA-11 PET1 68Ga-PSMA-11 Template biopsy 6- month follow-up + mpMRI (confirm negative (targeted
Slide 56: A personalized diagnostic pathway with Ga-PSMA-PET
A personalized diagnostic pathway with Ga-PSMA-PET Smarter triage BEFORE biopsy. Integrating imaging with biopsy Risk stratification Image-guided biopsy Symptoms or PSMA-PET + Potential high risk Staging and surgical elevated PSA mpMRI1 (PI-RADS2 5) planning Ga-PSMA-PET at diagnosis aims to: • Impro
Slide 57: 68Ga has a lower propensity for indeterminate bone lesions
68Ga has a lower propensity for indeterminate bone lesions (IBLs)1,2 Free 68Ga, in contrast to 18F, does not have an affinity to bone With 18F, a number of benign bone lesions accumulate PSMA and result in false positives on PSMA-PET/CT. SNMMI Guidelines for Prostate Cancer Imaging There are numerou
Slide 58: Case study: diagnostic accuracy of 68Ga-PSMA-11
Case study: diagnostic accuracy of 68Ga-PSMA-11 CT PET PET/CT Fused F-18 PSMA PET Scan PSA 3.4 • Patient on active surveillance • No active treatment IBL detected No rib lesion 68Ga-PSMA-11 PET Scan 6 months later Resolution without interval treatment confirms lesion benignity Patient representative
Slide 59: The future of prostate cancer detection
The future of prostate cancer detection • 72 year old male was negative for Current state suspicious findings 3 MRI acquisitions (PI-RADS <3) • PSMA PET detected a focal uptake in the right anterior apex of the prostate1 Future state 1 PSMA PET scan Patient representative scans – individual results
Slide 60: Mr. Kevin Richardson
Mr. Kevin Richardson CEO of Precision Medicine
Slide 61: Current state: PSMA-PET transformed staging and BCR detection
Current state: PSMA-PET transformed staging and BCR detection Initial biopsy protocol has remained unchanged since the addition of MRI Current indications PSMA-PET scans Current TAM: Future indications (in thousands) ~670,000 scans/year Total addressable market BCR 460 Response Initial to treatment
Slide 62: Future state: revolutionizes biopsy decision-making
Future state: revolutionizes biopsy decision-making Potential to double the size of the existing PSMA market 1M+1 Current indications Future indications Total addressable market 821,000 Biopsies reduced scans/ year Move imaging utilization to the pre-biopsy stage BCR Response to Monitoring treatment
Slide 63: Patient preference overwhelmingly favors Ga-PSMA PET scan over biopsy
Patient preference overwhelmingly favors Ga-PSMA PET scan over biopsy Survey (n = 1,002 patients who had prostate biopsy in the last 6 years)1 Want their doctor to discuss PSMA Would have preferred 93% PET + MRI in future biopsy decisions 95% MRI + PSMA PET prior to biopsy 88% Would bring up PSMA PE
Slide 64: $20B opportunity in Prostate Cancer
$20B opportunity in Prostate Cancer U.S. TAM (Patients) Target Indication USD $ ~670,000 scans Illuccix / Gozellix (Initial Staging, BCR, RLT selection) $2.7B (~327k patients) Precision Medicine ~821,000 scans BiPASS® (diagnosis of prostate cancer) $3.3B (~821k patients) ~266,900 scans Monitoring RL
Slide 65: Renal Cancer Overview
Renal Cancer Overview Dr. Sumanta (Monty) Pal, MD City of Hope
Slide 66: Disease overview: Kidney cancer
Disease overview: Kidney cancer Age-standardized rate per 100,000 (2022)4 14th most commonly diagnosed cancer worldwide1 Age-standardized incidence & mortality highest in North America & Europe1 Twice as common in men vs women1 90% of kidney cancer is RCC, of which ~85% is ccRCC2,3 ccRCC, clear cell
Slide 67: Significant unmet medical need in ccRCC
Significant unmet medical need in ccRCC Disease Treatment Need for Better Burden Challenges Tolerated Therapies ccRCC is a serious disease 20–40% of patients with localized 4,700 patients/year in the U.S. with substantial morbidity ccRCC ultimately progress⁵ need third-line therapy options⁸ and mort
Slide 68: Novel target in ccRCC - CAIX
Novel target in ccRCC - CAIX • Transmembrane glycoprotein involved in oxygen-sensing pathways and regulator for pH1,2 • Induced by hypoxia or by mutation of the Von Hippel-Lindau tumor suppressor gene1-4 • Expressed in >95% of ccRCC5-7 • Negligible expression in normal kidney tissue7 Adapted from Be
Slide 69: CAIX targeting in ccRCC
CAIX targeting in ccRCC Normal cells ccRCC • VHL mutation is pathognomonic for ccRCC, leading to HIF stabilization, accumulation, and tumor growth1 • CAIX is a target of HIF transcriptional activity under hypoxic conditions2 • CAIX is a transmembrane protein and a tumor-specific protein important fo
Slide 70: Monoclonal antibody-based theranostics
Monoclonal antibody-based theranostics TLX250-Tx for treatment of ccRCC and TLX250-Px for imaging Girentuximab Payload: 89Zr (imaging) Payload: 177Lu (therapy) • IgG1 kappa light chain chimeric • Positron emitter • Medium-energy β-emitter monoclonal antibody • Half-life 6.7 days • Half-life 3.3 days
Slide 71: Patient journey for a metastatic kidney cancer patient
Patient journey for a metastatic kidney cancer patient Unmet needs remain in improving efficacy in 1L and 2L treatments and outcomes in 3L+ therapies Diagnosis and Surgery 1L therapy 2L therapy 3L+ therapy Oligometastatic1: Active Surveillance or SBRT or IO-Exposed: Metastasectomy TKI5 or Disease Di
Slide 72: ccRCC administered activity schedule rationale
ccRCC administered activity schedule rationale 1 Observations from prior studies (Phase 1, n=23; Phase 2, n=14)1,2 ● Patients receiving the maximum number of cycles (3) were predominantly in the lower administered activity* cohorts (80% at ≤3145 MBq; none >4088 MBq) ● More treatment cycles correlate
Slide 73: TLX250-Tx: LUTEON (Ph3) and LUTEON-ATLAS (Ph2a) trial design
TLX250-Tx: LUTEON (Ph3) and LUTEON-ATLAS (Ph2a) trial design U.S. FDA ‘May Proceed’ received / EU under review US/EU: LUTEON-ATLAS (Ph2a) HREC approval received1 AUS: LUTEON (Ph3) Safety Lead-in* Part 1: Dose Optimization (Phase 2a) Part 2 (Phase 3) Population: N=3 N=TBD • Advanced or metastatic ccR
Slide 74: Zircaix (TLX250-Px)
Zircaix (TLX250-Px)1 Dr David Cade Group Chief Medical Officer, CMO 1 Zircaix brand name subject to regulatory approval.
Slide 75: Unmet need in diagnosis of ccRCC
Unmet need in diagnosis of ccRCC The most common – and one of the most aggressive – forms of renal cancer Need for early & accurate diagnosis / treatment • Up to 85% of RCCs are ccRCC1,2 Stage I • ccRCC causes ~90% of deaths of all RCC3,4 Tumor <7 cm in greatest dimension and limited to • For patien
Slide 76: TLX250-Px: Highly accurate in detecting ccRCC
TLX250-Px: Highly accurate in detecting ccRCC1 Phase 3 ZIRCON trial validates CAIX as a novel target ZIRCON study results summary 89Zr-girentuximab Primary endpoints: Sensitivity: 86% | Specificity: 87% (n=284) • IgG1 CAIX-targeting mAb • Payload: 89Zr, positron emitter with T1/2 ≤4 cm (n=145) • Sen
Slide 77: TLX250-Px: Patient case study
TLX250-Px: Patient case study 1 Clinical utility in real-world setting Clinical background: Initial small renal mass detected. CT and MRI demonstrated bilateral masses cT1a (2-4cm), no evidence of extended disease. Initial plan: partial nephrectomy and radioablation Negative 89Zr-girentuximab scan F
Slide 78: TLX250-Px: Patient case 2
TLX250-Px: Patient case 2 Detection of metastatic ccRCC Clinical background: 78 year old male with biopsy-confirmed ccRCC and metastases Clinical challenge: Patients with ccRCC frequently develop extension of tumor into renal vein and inferior vena cava. Distinguishing tumor thrombus from bland thro
Slide 79: Mr. Kevin Richardson
Mr. Kevin Richardson CEO, Precision Medicine
Slide 80: Building on existing relationships with referring physicians
Building on existing relationships with referring physicians TLX250-Px, Illuccix and Gozellix share common referral stakeholders Patient Presentation Imaging Treatment/Management Urologist Primary Care Urologist Physician Medical Oncologist Radiologist /Nuclear Medicine Physician Radiation Oncologis
Slide 81: $4.5B opportunity in Renal Cell Carcinoma
$4.5B opportunity in Renal Cell Carcinoma U.S. TAM (Patients) Target Indication USD $ ~116,320 Scans Precision Medicine Diagnosing indeterminant renal masses $600M (~116k patients) ~56,650 Scans Detection of localized and metastatic recurrence of ccRCC $300M (~23k patients) Therapeutics ~4,700 TLX25
Slide 82: Brain Cancer overview
Brain Cancer overview Dr. Arthur Braat University Medical Center Utrecht
Slide 83: Disease overview: Glioblastoma (GBM)
Disease overview: Glioblastoma (GBM) Burden of GBM is increasing, however survival rates have not improved in 20+ years1 ~25k new brain and CNS Annual Incidence (US)1 Average Survival (US)1 tumor cases/yr with ~18k 4 60 deaths/yr (U.S.)1 GBM is the most common and Relative Survival (%) Rate per 100,
Slide 84: Treatment options for GBM remain a significant unmet need
Treatment options for GBM remain a significant unmet need First line GBM treatment includes maximal safe surgical Glioblastoma patient journey resection followed by radiochemotherapy Diagnosis • Most patients progress after ~7 months1 First Line treatment • Recurrence occurs in 90% of patients withi
Slide 85: A novel mechanism of action overcoming the blood brain barrier
A novel mechanism of action overcoming the blood brain barrier Targeted radiation that provides imaging and therapeutic potential Pixclara TLX101-Tx (131I) • Large amino acid transporters, LAT1 and LAT2 are C TLX102-Tx (211At) highly expressed in gliomas1,2 compared to normal S-S tissue Blood (lumin
Slide 86: First-in-class, therapeutic candidates in GBM and LMD
First-in-class, therapeutic candidates in GBM and LMD Competitive de-risked portfolio Competitive advantages TLX101-Tx Orphan Drug Designation, • Readily passes blood-brain-barrier, a major ODD in glioma challenge in GBM treatment1,2 (U.S. & EU) • IV administration vs intracranial administration3 •
Slide 87: Prior studies have demonstrated favorable safety profile and encouraging efficacy in malignant gliomas
Prior studies have demonstrated favorable safety profile and encouraging efficacy in malignant gliomas Demonstrated safety and Demonstrated early Ongoing trials tolerability profile in combination efficacy results trials with EBRT and TMZ • IPAX-1 (Phase 1), IPAX Linz1 • Median OS of 23mo. (IPAX-1)
Slide 88: A global Phase 3 study for TLX101-Tx
TM , A global Phase 3 study for TLX101-Tx Part 1: Dose optimization Part 2: Randomized treatment expansion TLX101-Tx + Primary endpoints (Part 1) TLX101-Tx Eligible TLX101-Tx Lomustine Data review (4 GBq) + Patients (4 GBq) + • Max tolerated dose, MTD and Lomustine Lomustine recommended dose for Par
Slide 89: TLX101-Tx, Compassionate use experience
TLX101-Tx, Compassionate use experience UMC Utrecht Real-world data from 14 patients 14 patients with recurrent disease • 10 Glioblastoma (GBM) patients • 2 oligodendroglioma patients (WHO G2) • 1 oligodendroglioma patient (WHO G3) • 1 astrocytoma patient (WHO G2) Heavily pretreated patients • all p
Slide 90: TLX101-Tx has demonstrated a favorable safety profile, with stable disease observed
TLX101-Tx, has demonstrated a favorable safety profile, with stable disease observed Safe and tolerable treatment - Grade 3 adverse events, cerebral edema (1), common for this condition, judged not likely due to TLX101-Tx - No Grade 4 adverse events MRI RANO Patients Stable disease (SD) 3 of 12 Prog
Slide 91: Case Study 1
Case Study 1 GBM, third recurrence (Stupp, re-debulking and Lomustine) OS 11.3 months Baseline [18F]FET Baseline MRI MRI after 2 cycles MR RANO unconfirmed Patient representative scans – individual results may vary. Progressive Disease No [18F]FET performed El Ghalbouni et al. Manuscript pending sub
Slide 92: Case study 2: Near complete response
Case study 2: Near complete response Patient with recurrent glioblastoma treated with TLX101-Tx Patient • 56 year old male, with progressive, treatment refractory glioblastoma Before • Inoperable due to its location • Treatment with TLX101-Tx initiated with 2 cycles of 5 GBq with 3 cycles of Lomusti
Slide 93: Case study 3: Oligodendroglioma
Case study 3: Oligodendroglioma Patient • 38-year-old male • Diagnosed 4 years ago • After resection, EBRT+TMZ, PVC and Lomustine • Treatment holiday, due to new seizures Key results • Significant reduction of tumor after 10 months • TLX101-Tx utility is not just limited to glioblastoma Baseline [18
Slide 94: IPAX-2, Phase 1 study for TLX101-Tx (newly diagnosed GBM)
IPAX-2, Phase 1 study for TLX101-Tx (newly diagnosed GBM) Met Primary endpoint: Max Tolerated Dose (MTD) of 5GBq x 2cycles + SoC achieved Dose escalation Primary endpoints • Safety and tolerability • Max tolerated dose and TLX101-Tx TLX101-Tx TLX101-Tx recommended dose (3 GBq) x 2 cycles (4 GBq) x2
Slide 95: TLX102-Tx
211 At TLX102-Tx
Slide 96: I-APACHE – FIH Study of TLX102-Tx in recurrent GBM
I-APACHE – FIH Study of TLX102-Tx in recurrent GBM An Investigator Lead Trial (led by Dr. Braat) - Phase 1 Dose Escalation trial 211At can be easily imaged compared to other α-emitters (SPECT phantom of 211At) Intra-arterial TLX102-Tx (211At) Phase 1 dose escalation in [18F]FET positive first recurr
Slide 97: Unmet medical need in Leptomeningeal Disease (LMD)
Unmet medical need in Leptomeningeal Disease (LMD) A rapidly progressive disease with limited treatment options Rapidly Severe Limited and Biological and Median survival progressive and neurological poorly effective anatomical estimated at 3.8- uniformly fatal morbidity: treatment barriers to 5.4 mo
Slide 98: Leptomeningeal disease – LAT-1 expression confirmed with [18F]-FET
Leptomeningeal disease – LAT-1 expression confirmed with [18F]-FET 4th recurrence PXA in 16 year old girl with leptomeningeal spread ? Patient representative scans – individual results may vary. 98
Slide 99: Pixclara
Pixclara Mr. Kevin Richardson CEO, Precision Medicine
Slide 100: First FDA approved imaging agent for gliomas (U.S.)
First FDA approved imaging agent for gliomas (U.S.) • Pixlumi ®1 MAA accepted in Europe • Included in National Comprehensive Cancer Network (NCCN®) guidelines • Inclusion in International guidelines: EANM/EANO/RANO/SNMMI • Expanding into new indication: brain metastases2 • Addresses high unmet need
Slide 101: Pixclara positioned for successful launch
Pixclara positioned for successful launch Strong existing awareness of Pixclara among prescribers ~70% ~80% of physicians surveyed indicated of referrers rely on NCCN they are ready to prescribe guidelines when ordering imaging Pixclara upon FDA approval for glioma Key Market Insights Majority of re
Slide 102: $3.5B opportunity in Neuro-Oncology
$3.5B opportunity in Neuro-Oncology U.S. TAM (Patients) Target Indication USD $ 21,200 Scans Characterization of Progression in Glioma Patients $106M (11k patients) Precision Medicine 16,800 Scans Radiation Planning in adult Glioma Patients $84M (16k patients) 100,000 Scans Characterization of Brain
Slide 103: TLX400-Tx
TLX400-Tx Dr. David N. Cade Group Chief Medical Officer, CMO
Slide 104: TLX400-Tx- Broad FAP expression supports pan-cancer potential
TLX400-Tx- Broad FAP expression supports pan-cancer potential TLX400-Tx • FAP present on more than 90% of epithelial cancers, identified as a potential target 68Ga-TLX400 After treatment with for molecular imaging and therapy imaging agent TLX400-Tx (4 cycles) Payload: 177Lu • Broad expression on tu
Slide 105: TLX400-Tx: High level of clinical confidence
TLX400-Tx: High level of clinical confidence Clinical benefit reported across multiple indications and in treatment refractory patients Dataset: Clinical data available in patients across multiple cancer types Cancer Patients (#) Median OS/PFS Tumour Response Safety: Treatment is well tolerated even
Slide 106: TLX400-Tx, Case study in breast cancer
TLX400-Tx, Case study in breast cancer Clinical data Imaging: FDG FAP FDG FAP FAP Patient 54-year-old breast cancer patient treated with TLX400-Tx after multiple lines of prior therapy1 Patient representative images, individual results may vary. Follow up scan Follow up scan Baseline scan post 4 cyc
Slide 107: TLX400-Tx, in patients with thyroid cancer
TLX400-Tx, in 19 patients with thyroid cancer1 Partial Response in patient treated with TLX400-Tx2 Imaging: FDG FAP FAP FAP FAP Outcome Result Medullary thyroid cancer (total) 19 patients Assessable for radiological 15 patients response3 Partial response (PR) 5 patients (33%) Stable disease (SD) 7 p
Slide 108: TLX66-Tx TLX300-Tx
TLX66-Tx TLX300-Tx Mr. Richard Valeix CEO, Therapeutics
Slide 109: TLX66-Tx: Investigator Initiated Trial
TLX66-Tx: Investigator Initiated Trial TLX66-Tx, 90Y-DTPA-besilesomab Targeting molecule / target: Value to patients Monoclonal Antibody / CD66 Targeted conditioning with TLX66-Tx will enable myeloablation for HSCT without Mechanism of Action high intensity chemo (HIC) regimen • 90Y-DTPA-besilesomab
Slide 110: Extensive clinical data in >90 patients across multiple malignancies
Extensive clinical data in >90 patients across multiple malignancies Excellent safety profile and encouraging long-term efficacy signals TLX66-Tx has been tested in >90 patients (including pediatric patients) across a range of hematological malignancies. Completed studies include: Encouraging long-t
Slide 111: TLX300-Tx: Program overview
TLX300-Tx: TLX300-Tx Clinical Trial Program overview Targeting molecule / target: Name: ZOLAR imaging study • Antibody (olaratumab)/ Description: 89Zr (imaging isotope) • Platelet-derived Growth Factor Evaluate the safety, Receptor alpha (PDGFRα) pharmacokinetics, biodistribution and dosimetry of 89
Slide 112: Closing Remarks
Closing Remarks Dr. Christian Behrenbruch Managing Director and Group CEO
Slide 113: A proven leader in Radiopharma innovation and execution
A proven leader in Radiopharma innovation and execution ~$1B 3 22 countries 4 Estimated 2026 sales Approved products on market Illuccix available Pivotal trials near readout Diversified, de-risked pipeline Vertically integrated leadership Transformational growth engine • PSMA, CAIX, LAT1 and FAP • E
Telix Pharmaceuticals — Investor Day (September 2026) on 6ix